Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H27N5O6 |
| Molecular Weight | 433.4583 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC(=O)N[C@@H](CNC(=O)C[C@H]1CC(=NO1)C2=CC=C(C=C2)C(N)=N)C(O)=O
InChI
InChIKey=SRRJCHGGTPFZSS-ZBFHGGJFSA-N
InChI=1S/C20H27N5O6/c1-2-3-8-30-20(29)24-16(19(27)28)11-23-17(26)10-14-9-15(25-31-14)12-4-6-13(7-5-12)18(21)22/h4-7,14,16H,2-3,8-11H2,1H3,(H3,21,22)(H,23,26)(H,24,29)(H,27,28)/t14-,16+/m1/s1
Roxifiban (also known as DMP754), a potent antiplatelet agent in inhibiting platelet aggregation, and has a high specificity and affinity for human platelet glycoprotein IIb/IIIa complex (GPIIb/IIIa) receptors. Roxifiban participated in clinical trials phase III for the treatment of peripheral arterial disorders. This drug was also well tolerated in patients with chronic stable angina pectoris and was studied in the treatment of heparin-induced thrombocytopenia, and thrombosis. However, the development of this drug appears to have been discontinued.
Approval Year
Sample Use Guides
Ninety-eight patients were randomized to receive either a placebo or 1 of 8 oral dosages of roxifiban. Twenty-two patients were enrolled in multiple-dose regimens, bringing the total study population to 120. The oral dosages were 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, or 2.5 mg/day for up to 30 days.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
170902-52-0
Created by
admin on Wed Apr 02 17:27:58 GMT 2025 , Edited by admin on Wed Apr 02 17:27:58 GMT 2025
|
PRIMARY | |||
|
177231
Created by
admin on Wed Apr 02 17:27:58 GMT 2025 , Edited by admin on Wed Apr 02 17:27:58 GMT 2025
|
PRIMARY | |||
|
DTXSID80168970
Created by
admin on Wed Apr 02 17:27:58 GMT 2025 , Edited by admin on Wed Apr 02 17:27:58 GMT 2025
|
PRIMARY | |||
|
R96EWZ6KUZ
Created by
admin on Wed Apr 02 17:27:58 GMT 2025 , Edited by admin on Wed Apr 02 17:27:58 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
